Axiom Biosciences to launch IPO on Hong Kong exchange before Nasdaq co‑listing

San Diego‑based Axiom Biosciences announced plans to go public with a primary listing on the Hong Kong Stock Exchange, followed later by a Nasdaq co‑listing, a structure it says is a first for a U.S. biotech.

The decision follows recent encouraging phase‑1 data for its lead stem‑cell therapy targeting two lethal newborn neurological disorders, a program developed together with South Korean partner Medinno.

Axiom, formerly known as Cytonus, raised $11.7 million in a Series A round in 2023 led by Seoul‑based Partners Investment and other Asian and U.S. investors, giving it an international shareholder base that supports a Hong Kong listing.

CEO Remo Moomiaie‑Qajar said the move reflects the company’s willingness to challenge conventional financing approaches and could open new capital‑raising pathways for biotech firms.